CZ2002488A3 - Transdermální podávání lasofoxifenu - Google Patents

Transdermální podávání lasofoxifenu Download PDF

Info

Publication number
CZ2002488A3
CZ2002488A3 CZ2002488A CZ2002488A CZ2002488A3 CZ 2002488 A3 CZ2002488 A3 CZ 2002488A3 CZ 2002488 A CZ2002488 A CZ 2002488A CZ 2002488 A CZ2002488 A CZ 2002488A CZ 2002488 A3 CZ2002488 A3 CZ 2002488A3
Authority
CZ
Czechia
Prior art keywords
drug
effective amount
transdermal
subject
skin
Prior art date
Application number
CZ2002488A
Other languages
Czech (cs)
English (en)
Inventor
David Fikstad
Danyi Quan
Original Assignee
Watson Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals, Inc. filed Critical Watson Pharmaceuticals, Inc.
Publication of CZ2002488A3 publication Critical patent/CZ2002488A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CZ2002488A 2000-06-01 2001-05-31 Transdermální podávání lasofoxifenu CZ2002488A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20878900P 2000-06-01 2000-06-01

Publications (1)

Publication Number Publication Date
CZ2002488A3 true CZ2002488A3 (cs) 2002-06-12

Family

ID=22776068

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2002488A CZ2002488A3 (cs) 2000-06-01 2001-05-31 Transdermální podávání lasofoxifenu

Country Status (24)

Country Link
US (1) US20020037311A1 (cg-RX-API-DMAC7.html)
EP (1) EP1229909B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003534368A (cg-RX-API-DMAC7.html)
KR (1) KR100795870B1 (cg-RX-API-DMAC7.html)
CN (1) CN1400897A (cg-RX-API-DMAC7.html)
AT (1) ATE253910T1 (cg-RX-API-DMAC7.html)
AU (2) AU785199B2 (cg-RX-API-DMAC7.html)
BR (1) BR0106680A (cg-RX-API-DMAC7.html)
CA (1) CA2380769A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2002488A3 (cg-RX-API-DMAC7.html)
DE (1) DE60101206T2 (cg-RX-API-DMAC7.html)
DK (1) DK1229909T3 (cg-RX-API-DMAC7.html)
ES (1) ES2210168T3 (cg-RX-API-DMAC7.html)
HK (1) HK1052472A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0202592A3 (cg-RX-API-DMAC7.html)
IL (2) IL147640A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02001152A (cg-RX-API-DMAC7.html)
NZ (1) NZ516582A (cg-RX-API-DMAC7.html)
PL (1) PL201222B1 (cg-RX-API-DMAC7.html)
PT (1) PT1229909E (cg-RX-API-DMAC7.html)
RU (1) RU2328276C2 (cg-RX-API-DMAC7.html)
TR (1) TR200400241T4 (cg-RX-API-DMAC7.html)
WO (1) WO2001091724A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200200519B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7564908B2 (en) * 2004-09-23 2009-07-21 Motorola, Inc. Method and apparatus for encryption of over-the-air communications in a wireless communication system
US7804912B2 (en) * 2004-09-23 2010-09-28 Motorola, Inc. Method and apparatus for encryption of over-the-air communications in a wireless communication system
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
FR2905601A1 (fr) * 2006-09-11 2008-03-14 Innoderm Sarl Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
EP2167001A4 (en) * 2007-07-10 2012-10-31 Agile Therapeutics Inc DEVICE FOR THE DERIVED ULTRASONIC WELDING
AU2008275101B2 (en) 2007-07-10 2014-08-21 Agile Therapeutics, Inc. Dermal delivery device with in situ seal
US20140378424A1 (en) * 2011-12-30 2014-12-25 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight
CN103751138A (zh) * 2013-12-31 2014-04-30 北京万全德众医药生物技术有限公司 一种含酒石酸拉索昔芬的口腔崩解片及其制备方法
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
CN103830207A (zh) * 2014-03-14 2014-06-04 崔书豪 一种酒石酸拉索昔芬贴膏剂
KR20180035209A (ko) * 2015-07-24 2018-04-05 킴벌리-클라크 월드와이드, 인크. 종양에 대한 활성제의 더 나은 전달 방법
US10737082B2 (en) * 2015-07-24 2020-08-11 Sorrento Therapeutics, Inc. Methods for lymphatic delivery of active agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
CA2208132A1 (en) * 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6203817B1 (en) * 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos

Also Published As

Publication number Publication date
RU2002105378A (ru) 2003-11-10
US20020037311A1 (en) 2002-03-28
IL147640A (en) 2007-03-08
PT1229909E (pt) 2004-04-30
PL201222B1 (pl) 2009-03-31
NZ516582A (en) 2004-08-27
PL354628A1 (en) 2004-02-09
IL147640A0 (en) 2002-08-14
WO2001091724A3 (en) 2002-05-30
DE60101206D1 (de) 2003-12-18
BR0106680A (pt) 2002-04-30
DE60101206T2 (de) 2004-09-02
ATE253910T1 (de) 2003-11-15
AU6523501A (en) 2001-12-11
KR100795870B1 (ko) 2008-01-21
MXPA02001152A (es) 2002-08-20
HK1052472A1 (zh) 2003-09-19
EP1229909B1 (en) 2003-11-12
HUP0202592A2 (hu) 2002-12-28
TR200400241T4 (tr) 2004-04-21
HUP0202592A3 (en) 2003-07-28
AU2007200426A1 (en) 2007-02-22
JP2003534368A (ja) 2003-11-18
WO2001091724A2 (en) 2001-12-06
KR20030025219A (ko) 2003-03-28
RU2328276C2 (ru) 2008-07-10
ZA200200519B (en) 2003-04-22
CN1400897A (zh) 2003-03-05
AU785199B2 (en) 2006-11-02
CA2380769A1 (en) 2001-12-06
EP1229909A2 (en) 2002-08-14
DK1229909T3 (da) 2004-03-15
ES2210168T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
CA2135925C (en) Use of glycerin in moderating transdermal drug delivery
JP2604097B2 (ja) 皮膚浸透増強剤としてソルビタンエステルを用いた経皮的に薬物を投与するための方法およびシステム
CA2217888C (en) Triacetin as a transdermal penetration enhancer
AU2007200426A1 (en) Transdermal delivery of lasofoxifene
JP6336476B2 (ja) ホルモン及びその他の薬剤を経皮送達するための組成物及び方法
AU5157098A (en) Fatty acid esters of lactic acid salts as permeation enhancers
US8246978B2 (en) Dermal delivery device with reduced loss of its volatile components
WO2005060540A2 (en) Norethindrone sustained release transdermal formulation
US20040037873A1 (en) Norethindrone sustained release formulations and methods associated therewith
TWI298253B (en) Transdermal delivery of lasofoxifene